HC Wainwright Reaffirms “Buy” Rating for Iterum Therapeutics (NASDAQ:ITRM)

Iterum Therapeutics (NASDAQ:ITRM)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 289.61% from the stock’s current price.

Iterum Therapeutics Stock Down 7.8 %

Shares of Iterum Therapeutics stock opened at $1.54 on Tuesday. The company has a market cap of $25.30 million, a P/E ratio of -0.52 and a beta of 2.36. The company has a debt-to-equity ratio of 3.63, a quick ratio of 1.89 and a current ratio of 1.89. Iterum Therapeutics has a one year low of $0.62 and a one year high of $2.50. The firm has a fifty day moving average of $1.52 and a two-hundred day moving average of $1.50.

Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.08. On average, analysts forecast that Iterum Therapeutics will post -1.75 earnings per share for the current year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.